Predictive effects of bilirubin on response of colorectal cancer to irinotecan-based chemotherapy

Figure 1 Serum total bilirubin and unconjugated bilirubin levels between UGT1A1*28 (TA)6/6 and (TA)6/7 or (TA)7/7 genotype. Patients with UGT1A1*28 (TA)6/7 or (TA)7/7 genotype had an increased likelihood of (A) higher TBil (P = 0.018) and (B) higher UBil (P = 0.014) levels compared with (TA)6/6 genotype. TBil: Total bilirubin; UBil: Unconjugated bilirubin.

Figure 2 Receiver operating characteristic analysis of AgeCoBil and AgeUGT1A1*28 in predicting objective response. AgeCoBil included age (as a continuous variable) and CoBil (as a trichotomous variable). AgeUGT1A1*28 included age and UGT1A1*28 genotypes (as a dichotomous variable). Classifier’s performance of CoBil and UGT1A1*28 was comparable. AUC: Area under the curve; TBil: Total bilirubin; UBil: Unconjugated bilirubin; CoBil: Combined TBil and UBil.